Sub-classification of intermediate-stage (Barcelona Clinic Liver Cancer stage-B) hepatocellular carcinomas

Table 1 Substaging of intermediate-stage; Bolondi substaging system

Intermediatesubstage	B1	B2	B3	B4
Child-Pugh score	5-7	5-6	7	8-9
Up-to-7 criterion	In	Out	Out	Any
1st option	TACE	TACE or TARE		BSC
Alternative	LT	Sorafenib	Research trial	LT
	TACE + Ablation		TACE
			Sorafenib
Median survival time (mo)	41.0	22.1	14.1	17.2

Modification from Reference[9,11]. TACE: Transarterial chemoembolization; TARE: Transarterial radioembolization; LT: Liver transplantation; BSC: Best supportive care.

Table 2 Substaging of intermediate-stage; proposal from japanese society of transcatheter hepatic arterial embolization

Intermediate-substage	B1	B2	B3
Child-Pugh score	5-6	5-8	9
4-of-7 cm criterion	In	In (CP 7-8)	Any
		or
		Out (CP 5-8)
2-yr survival rate	77.2%	59.5%	16.7%
Median survival time (mo)	40.5	28.1	13.0

CP: Child-Pugh.